文献速递腹部技术与安全PETMRCT

交界可切除与局部进展期胰腺癌:FDG PET/MRI与CT肿瘤指标评估新辅助治疗病理反应及预测生存

Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
PubMed 文献 · AJR Am J Roentgenol · 2020-10-21

本回顾性研究纳入44例治疗前PET/MRI显示18F-FDG高摄取的交界可切除或局部进展期胰腺导管腺癌患者,于新辅助治疗前后行PET/MRI(34例另有CT形态学指标),比较病理反应者(CAP 0-1级)与非反应者(CAP 2-3级)的指标。治疗后完全代谢反应、ΔSUVmax、ΔSUVgluc、RECIST反应及ΔTvol在两组间有差异,且与病理反应和总生存相关;治疗前CA 19-9及各项影像指标两组无差异。

要点

  • 新辅助治疗后完全代谢反应者占89%(17/19),非反应者占40%(10/25),AUC 0.75。
  • ΔSUVgluc的AUC最高(0.87),ΔTvol为0.86,ΔSUVmax为0.83,RECIST为0.71。
  • 总生存与完全代谢反应(p=.03)、ΔSUVmax(p=.003)、ΔSUVgluc(p=.003)及RECIST(p=.046)相关。

核心结论

  • 与新辅助治疗前CA 19-9水平不同,治疗后PET/MRI代谢指标变化和CT形态学指标变化与胰腺导管腺癌病理反应及总生存相关,原文指出需前瞻性验证。
  • 治疗前反应者与非反应者在CA 19-9水平、代谢指标及CT指标上均无差异(p>.05)。

研究设计与样本

  • 回顾性研究,纳入2016年8月至2019年2月间44例治疗前PET/MRI显示18F-FDG高摄取的交界可切除或局部进展期胰腺导管腺癌患者,均在新辅助治疗后、手术前行PET/MRI。
  • 病理反应以College of American Pathologists评分0和1级为反应者、2和3级为非反应者;34例有CT形态学指标。
  • 采用Cox比例风险模型评估指标与总生存的关系,并对与病理反应显著相关的指标计算AUC。

诊断标准与关键数值

  • 完全代谢反应者占89%(17/19)vs 非反应者占40%(10/25),p=.04;完全代谢反应预测病理反应的AUC为0.75。
  • ΔSUVmax反应者为-70%±13% vs 非反应者为-37%±42%(p<.001),AUC为0.83。
  • ΔSUVgluc反应者为-74%±12% vs 非反应者为-30%±58%(p<.001),AUC为0.87。
  • CT上RECIST反应者占93%(13/14)vs 非反应者占50%(10/20),p=.02,AUC为0.71。
  • ΔTvol反应者为-85%±21% vs 非反应者为57%±400%(p<.001),AUC为0.86;双变量PET/MRI与CT模型AUC分别为0.83(完全代谢反应与ΔSUVmax)、0.87(完全代谢反应与ΔSUVgluc)、0.87(RECIST与ΔTvol)。

临床应用与阅片要点

  • 原文结论指出,与新辅助治疗前CA 19-9不同,治疗后PET/MRI代谢指标变化和CT形态学指标变化与病理反应及总生存相关,原文提出需前瞻性验证。
  • 原文临床影响部分提出,与病理反应和总生存相关的影像指标可能有助于指导接受急诊治疗干预的胰腺导管腺癌患者的临床管理和结局。

局限性

  • 原文结论指出需前瞻性验证(warranting prospective validation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Imaging biomarkers of response to neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDA) are needed to optimize treatment decisions and long-term outcomes. OBJECTIVE. The purpose of this study was to investigate metrics from PET/MRI and CT to assess pathologic response of PDA to NAT and to predict overall survival (OS). METHODS. This retrospective study included 44 patients with 18F-FDG-avid borderline resectable or locally advanced PDA on pretreatment PET/MRI who also underwent post-NAT PET/MRI before surgery between August 2016 and February 2019. Carbohydrate antigen 19-9 (CA 19-9) level, metabolic metrics from PET/MRI, and morphologic metrics from CT (n = 34) were compared between pathologic responders (College of American Pathologists scores 0 and 1) and nonresponders (scores 2 and 3). AUCs were measured for metrics significantly associated with pathologic response. Relation to OS was evaluated with Cox proportional hazards models. RESULTS. Among 44 patients (22 men, 22 women; mean age, 62 ± 11.6 years), 19 (43%) were responders, and 25 (57%) were nonresponders. Median OS was 24 months (range, 6-42 months). Before treatment, responders and nonresponders did not differ in CA 19-9 level, metabolic metrics, or CT metrics (p > .05). After treatment, responders and nonresponders differed in complete metabolic response (CMR) (responders, 89% [17/19]; nonresponders, 40% [10/25]; p = .04], mean change in SUVmax (ΔSUVmax; responders, -70% ± 13%; nonresponders, -37% ± 42%; p < .001), mean change in SUVmax corrected to serum glucose level (ΔSUVgluc) (responders, -74% ± 12%; nonresponders, -30% ± 58%; p < .001), RECIST response on CT (responders, 93% [13/14]; nonresponders, 50% [10/20]; p = .02)], and mean change in tumor volume on CT (ΔTvol) (responders, -85% ± 21%; nonresponders, 57% ± 400%; p < .001). The AUC of CMR for pathologic response was 0.75; ΔSUVmax, 0.83; ΔSUVgluc, 0.87; RECIST, 0.71; and ΔTvol 0.86. The AUCs of bivariable PET/MRI and CT models were 0.83 (CMR and ΔSUVmax), 0.87 (CMR and ΔSUVgluc), and 0.87 (RECIST and ΔTvol). OS was associated with CMR (p = .03), ΔSUVmax (p = .003), ΔSUVgluc (p = .003), and RECIST (p = .046). CONCLUSION. Unlike CA 19-9 level, changes in metabolic metrics from PET/MRI and morphologic metrics from CT after NAT were associated with pathologic response and OS in patients with PDA, warranting prospective validation. CLINICAL IMPACT. Imaging metrics associated with pathologic response and OS in PDA could help guide clinical management and outcomes for patients with PDA who undergo emergency therapeutic interventions.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Panda A, Garg I, Truty MJ, et al. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival. AJR Am J Roentgenol. 2020. PMID: 33084382. doi:10.2214/AJR.20.24567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。